Inhibition of Sodium/Hydrogen Exchanger‐1 in the Right Ventricle and Lung Dysfunction Induced by Experimental Pulmonary Arterial Hypertension in Rats
By specifically inhibiting NHE-1, rimeporide at the selected dosage revealed remarkable anti-PAH effects by preventing the functional, morphological, and biochemical deleterious effects of PAH on the right ventricle and lungs. Rimeporide should be considered as a potential treatment for PAH.
Authors
- Melanie Reinero
- Maurice Beghetti (ORCID: https://orcid.org/0000-0002-1841-0927)
- Michele Samaja (ORCID: https://orcid.org/0000-0002-0705-340X)
- Florence Porte (ORCID: https://orcid.org/0000-0001-6932-5784)
- Piergiorgio Tozzi (ORCID: https://orcid.org/0000-0002-2608-7568)
- Julien Puyal (ORCID: https://orcid.org/0000-0002-8140-7026)
- Giuseppina Milano (ORCID: https://orcid.org/0000-0002-4554-9465)
Institutions
- University of Geneva (CH)
- University of Milan (IT)
- Centre Hospitalier Universitaire Vaudois (CH)
- University Hospital of Geneva (CH)
- University Centre of Legal Medicine (CH)
- EspeRare Foundation (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1161/jaha.124.036859
- Citations
- 4
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Université de Lausanne
- Centre Hospitalier Universitaire Vaudois